U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 11 - 20 of 742 results

Status:
Investigational
Source:
INN:remetinostat [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

METHYLPARABEN SUBEROHYDROXAMIC ACID PHENYL ESTER (more known as Remetinostat), a histone deacetylase (HDAC) inhibitor, was developed for the treatment of cutaneous T cell lymphoma (CTCL). This drug is participating in phase II clinical trial to evaluate the efficacy, safety, and tolerability to skin lesions in patients with early-stage cutaneous T-cell lymphoma. In May 2019 was announced the positive results from phase II trial of remetinostat in basal cell carcinoma (BCC) patients. Initial results suggest that remetinostat gel offers a potentially effective and well-tolerated, non-surgical intervention for the treatment of localized BCCs. The unique design of remetinostat enables topical application, making it active only in the skin. As soon as it reaches the blood stream, it is degraded, avoiding the side effects associated with other HDAC inhibitors. Besides, remetinostat was studied as the treatment of plaque psoriasis; however, this study was discontinued.
Status:
Investigational
Source:
INN:propanocaine
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Propanocaine is a benzyl alcohol derivative with local anesthetics activity
Status:
Investigational
Source:
JAN:EMITEFUR [JAN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Emitefur or BOF-A2 is a fluorinated pyrimidine antimetabolite exerting antineoplastic properties. It is a compound composed of 5-fluorouracil (5-FU) and 3-cyano-2,6-dihydroxypyridine (CNDP), an inhibitor of 5-FU degradation by dihydrouracil dehydrogenase in order to prolong the blood 5-FU level as well as increase selective toxicity to a tumor. Emitefur demonstrated clinical activity in preliminary studies in Japan. Emitefur development for the treatment of solid tumors has been discontinued.
Status:
Investigational
Source:
INN:larotaxel [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Targets:

LAROTAXEL is a taxoid with potential antineoplastic activity. It prevents microtubule depolymerization, thereby inhibiting cell proliferation. It displays a broad spectrum of antitumor activity in vitro and in vivo, including activity against P-glycoprotein expressing tumors. LAROTAXEL was in phase III clinical trials for the treatment of breast cancer, pancreatic cancer, and bladder cancer. However, its development was discontinued.
Status:
Investigational
Source:
INN:broxaldine
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


Broxaldine, also known as brobenzoxaldine, is a dibromo derivative of quinaldine. It was used in combination with other halogenated hydroxyquinoline compound broxyquinoline (INTESTOPAN) for the treatment of intestinal amoebiasis and childhood diarrhea. In a specific ratio of 5/1, they were shown to act synergistically against several pathogens.
Status:
Investigational
Source:
INN:benzodrocortisone [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
NCT00753168: Phase 1/Phase 2 Interventional Completed Glaucoma, Open-Angle
(2008)
Source URL:

Class (Stereo):
CHEMICAL (EPIMERIC)

Othera Pharmaceuticals originally developed OT-730 (now known as QLT 091568) as an oculoselective beta-blocker for reducing the elevated intraocular pressure associated with glaucoma. OT-730 was involved in phase II clinical trial in patients with ocular hypertension or open-angle glaucoma. However, these studies were discontinued. At December 30, 2009, QLT Inc. acquired OT-730.
Status:
Investigational
Source:
INN:asalhydromorphone [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:etripamil [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Etripamil is a non-dihydropyridine, L-type calcium channel blocker. Currently, etripamil is in Phase 3 development for the treatment of paroxysmal supraventricular tachycardia. Milestone Pharmaceuticals is also developing etripamil to provide rapid heartbeat control for patients living with atrial fibrillation and acute symptom relief for patients with angina.
Status:
Investigational
Source:
INN:lotamilast [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


E-6005 is a novel PDE4 inhibitor developed as a topical agent for atopic dermatitis (AD). It potently and selectively inhibited human PDE4 activity and suppressed the production of various cytokines from human lymphocytes and monocytes. In mice models, the topical application of E6005 produced an immediate antipruritic effect as well as an anti-inflammatory effect with reduced expression of cytokines/adhesion molecules. E-6005 increases the cutaneous concentration of cAMP to relieve dermatitis-associated itching. E-6005 may be a promising novel therapeutic agent with antipruritic activity for the treatment of AD. E-6005 is currently in phase 2 development for patients with mild-to-moderate atopic dermatitis.

Showing 11 - 20 of 742 results